LFVN
NasdaqLifevantage Corp
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-06-30
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$220.2M
2021
$206.4M
2022
$213.4M
2023
$200.2M
2024
$228.5M
2025
Snapshot
SEC EDGAR · FY 2025-06-30Revenue$228.5M
Net Income$9.8M
Gross Profit$183.7M
Oper Income$12.2M
EPS (dil)$0.75
Rev/sh$18.11
FCF/sh$0.83
Book/sh$2.75
Gross M80.4%
Oper M5.3%
Profit M4.3%
FCF M4.6%
ROE28.3%
ROA13.6%
ROIC67.7%
R&D/Rev0.6%
Rev Y/Y14.2%
Rev 3Y CAGR3.5%
EPS Y/Y226.1%
EPS 3Y CAGR46.2%
FCF 3Y CAGR17.8%
Payout21%
Div/sh—
Shs Chg Y/Y0%
Current Ratio1.87
Quick Ratio1.11
Debt/Eq—
Int Coverage—
Net Debt—
Total Debt—
Cash & Eq$20.2M
Total Assets$72.0M
Oper CF$11.9M
Capex$1.4M
Free CF$10.5M
Buybacks$3.1M
Equity$34.6M
Liabilities$37.3M
Shs Outstand0.01B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $220.2M | $206.4M | $213.4M | $200.2M | $228.5M |
| Gross Profit | $182.0M | $168.3M | $170.0M | $158.7M | $183.7M |
| Operating Income | $17.6M | $7.6M | $4.3M | $4.3M | $12.2M |
| Net Income | $12.9M | $3.1M | $2.5M | $2.9M | $9.8M |
| Diluted EPS | $0.90 | $0.24 | $0.20 | $0.23 | $0.75 |
| Operating Cash Flow | $16.3M | $8.0M | $6.8M | $12.2M | $11.9M |
| Free Cash Flow | $12.5M | $6.4M | $3.8M | $10.0M | $10.5M |
COMMUNITY · $LFVN0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.